Advertisement Boehringer, Eureka Therapeutics to develop new antibodies for cancer treatment - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Boehringer, Eureka Therapeutics to develop new antibodies for cancer treatment

German pharmaceutical firm Boehringer Ingelheim has entered into a research agreement with US-based Eureka Therapeutics to discover new therapeutic antibodies in oncology.

Boehringer Corp_build

Under the deal, Eureka will apply its proprietary human sequence antibody libraries and its technology platform to discover antibodies recognizing intracellular proteins, which represent about 90% of cancer-specific targets.

Boehringer will select cancer-specific peptides that can be displayed via the major histocompatibility complex (MHC-complex) on the cell surface to develop better therapies for cancer patients.

In addition, Boehringer will have the option to conduct further development and commercialization of the antibodies.

Eureka Therapeutics president and CEO Cheng Liu said: "We are excited to partner with Boehringer Ingelheim, a leader in oncology research and development to develop next generation cancer immunotherapies targeting intracellular oncogenes.

"Intracellular oncogenes represent 90% of cancer-specific antigens, many of which were considered ‘undruggable targets’ until recently.

"This collaboration builds upon Eureka’s success in discovery and development of fully human antibodies against intracellular oncogenes. We look forward to working with Boehringer Ingelheim to advance the immuno-oncology frontier and address some of the most challenging unmet medical needs."

The deal will see Eureka receive an undisclosed upfront technology access fee and research funding for each program, and may receive technical success fees, option exercise fees, and other downstream payments.


Image: Boehringer Ingelheim’s corporate headquarters in Ingelheim, Germany. Photo: courtesy of Boehringer Ingelheim GmbH.